Top Markets
#1 Black Phoenix Black Phoenix +21,392.78%
#2 Nesa Nesa +679.37%
#3 Cortex Cortex +92.11%
#4 Ontology Gas Ontology Gas +77.46%
#5 Kinesis Silver Kinesis Silver +54.91%
#6 Magma Finance Magma Finance +25.67%
#7 Biconomy Biconomy +25.24%
#8 QuantixAI QuantixAI +23.07%
#9 EXOD EXOD +22.78%
#10 SAFEcoin SAFEcoin +20.88%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087
Rank in Stocks #3120
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Share Price
$10.33
Market Cap
$6.18B
Change (1 day)
3.66%
Change (1 year)
4.21%
Country
CN
Trade Gan & Lee Pharmaceuticals. (603087)

Category

Healthcare
Revenue for Gan & Lee Pharmaceuticals. (603087)
Revenue in Aug 2026 TTM: 0
According to Gan & Lee Pharmaceuticals. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Gan & Lee Pharmaceuticals. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Intuitive Surgical, Inc. Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
ISRG.US
 $11.03B -
US
EssilorLuxottica S.A. EssilorLuxottica S.A.
EssilorLuxottica S.A.
EL.PA
 $34.74B -
FR
HOYA Corporation HOYA Corporation
HOYA Corporation
7741.T
 - -
JP
Becton, Dickinson and Company Becton, Dickinson and Company
Becton, Dickinson and Company
BDX.US
 $20.84B -
US
Alcon Inc. Alcon Inc.
Alcon Inc.
ALC.SW
 - -
CH